Charles River announced a strategic collaboration within the acceleration program DanubeNeuro, an initiative focused on identifying and advancing pioneering academic research projects with the potential to create new drugs and technologies in the field of neurodegeneration. Cebina’s DanubeNeuro acceleration program identifies and develops research projects with the potential to create drugs, diagnostic methods, disease biomarkers, and imaging techniques for neurodegenerative diseases.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River, Insightec team on therapy in neuroscience with FUS
- Charles River price target lowered to $203 from $228 at TD Cowen
- Charles River price target lowered to $215 from $235 at Morgan Stanley
- Charles River price target lowered to $240 from $300 at Deutsche Bank
- Charles River price target lowered to $210 from $230 at Barclays